RT Journal Article
SR Electronic
T1 Detection of Neuroendocrine Tumors: <sup>99m</sup>Tc-P829 Scintigraphy Compared with <sup>111</sup>In-Pentetreotide Scintigraphy
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 889
OP 895
VO 43
IS 7
A1 Rachida Lebtahi
A1 Joseph Le Cloirec
A1 Claire Houzard
A1 Doumit Daou
A1 Iradj Sobhani
A1 Geneviève Sassolas
A1 Michel Mignon
A1 Patrick Bourguet
A1 Dominique Le Guludec
YR 2002
UL http://jnm.snmjournals.org/content/43/7/889.abstract
AB The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 μg somatostatin analog labeled with 148 ± 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 μg peptide labeled with 991.6 ± 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results: 111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P &lt; 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy. Conclusion: In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.